Dashboard Market News Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Rigel Pharmaceuticals Inc banner

Rigel Pharmaceuticals Inc
NASDAQ:RIGL

Watchlist Manager
Rigel Pharmaceuticals Inc Logo
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Watchlist
Price: 47.38 USD 0.21% Market Closed
Market Cap: $876.5m
Write Note Create Alert Ask AI

Wall St Price Targets

RIGL Price Targets Summary
Rigel Pharmaceuticals Inc

Wall Street analysts forecast RIGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RIGL is 56.1 USD with a low forecast of 43.43 USD and a high forecast of 89.25 USD.

RIGL Lowest Forecast
Wall Street Target
$43.43
-8% Downside
RIGL Average Forecast
Wall Street Target
$56.1
18% Upside
RIGL Highest Forecast
Wall Street Target
$89.25
88% Upside
Lowest Forecast
Price Target
43.43 USD
8% Downside
Average Forecast
Price Target
56.1 USD
18% Upside
Highest Forecast
Price Target
89.25 USD
88% Upside
Rigel Pharmaceuticals Inc Competitors:
Price Targets

Revenue
Forecast

45% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
45% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 45%. The projected CAGR for the next 8 years is 5%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

The compound annual growth rate for Gross Profit over the next 3 years is 18%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

The compound annual growth rate for Operating Income over the next 8 years is 3%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is -2%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is -6%.

What are analyst estimates?

Continue RIGL Research

Summary
RIGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RIGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RIGL stock valuation using valuation multiples.
Wall St Estimates
RIGL price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RIGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RIGL's stock price target?
Price Target
56.1 USD

According to Wall Street analysts, the average 1-year price target for RIGL is 56.1 USD with a low forecast of 43.43 USD and a high forecast of 89.25 USD.

What is the Revenue forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 45%. The projected CAGR for the next 8 years is 5%.

What is the Gross Profit forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
18%

The compound annual growth rate for Gross Profit over the next 3 years is 18%.

What is the Operating Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
3%

The compound annual growth rate for Operating Income over the next 8 years is 3%.

What is the Pre-Tax Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-2%

The compound annual growth rate for Pre-Tax Income over the next 3 years is -2%.

What is the Net Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-6%

The compound annual growth rate for Net Income over the next 8 years is -6%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.